 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Course Overview and Fundamentals of Qualification

Impurities in New Drug Products (Degradation Products)

Considerations for Qualification of Degradation Products

Advanced Application and Risk Assessment

Case Study Applications in Degradation Analysis

Practical Execution of Qualification Strategies

Audit and Inspection-Readiness for Degradation Products

Assessment Quizzes

Knowledge Check: Thresholds and Regulatory Logic

Scenario-Based Qualification Assessment

Comprehensive Threshold and Mutagenicity Assessment

Regulatory Takeaways Assessment

Key Concepts and Workflow Synthesis

Course Surveys and Feedback

Professional Reflection and Capability Assessment

Course Overview and Alignment Survey

Welcome to the definitive course on "Evaluating and Qualifying Degradation Products per ICH Q3B(R2)". In the highly regulated pharmaceutical industry, ensuring the safety and efficacy of new drug products is paramount.

Welcome to the definitive course on "Evaluating and Qualifying Degradation Products per ICH Q3B(R2)". In the highly regulated pharmaceutical industry, ensuring the safety and efficacy of new drug products is paramount. A critical component of this process is the rigorous evaluation and qualification of degradation products—impurities that form during the manufacturing or storage of a drug. This comprehensive online course is meticulously designed to guide regulatory affairs professionals, CMC (Chemistry, Manufacturing, and Controls) specialists, and analytical scientists through the complexities of the ICH Q3B(R2) guidelines.

Throughout this course, you will dive deep into the fundamental concepts of degradation product qualification, exploring the biological safety rationale and understanding the critical exclusions of the Q3B(R2) scope. We will demystify the dose-dependent thresholds for reporting, identification, and qualification, providing you with the practical knowledge to navigate the "whichever is lower" logic and the Attachment 3 decision tree.

Beyond theory, this course emphasizes real-world application. You will engage with advanced case studies, analyze borderline stability situations, and formulate risk-based recommendations for unidentified peaks and structural alerts for mutagenicity (interfacing with ICH M7). Furthermore, you will learn how to design compliant qualification strategies, avoid common regulatory traps, and build robust, inspection-ready documentation. By the end of this program, you will possess the expertise to confidently escalate stability data deviations, justify regulatory submissions, and ultimately protect patient safety while sustaining product approval. Enroll today to master the evaluation and qualification of degradation products and elevate your pharmaceutical compliance expertise.

120. Evaluating and Qualifying Degradation Products per ICH Q3B(R2)

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>The evaluation and qualification of degradation products in new drug products represent a critical juncture in pharmaceutical development and lifecycle management. Governed by the ICH Q3B(R2) guideline, this process requires a rigorous, data-driven approach to establish biological safety when degradants exceed specified regulatory thresholds. This course provides an advanced examination of the fundamental concepts, biological safety rationales, and precise scope of Q3B(R2), explicitly differentiating its parameters from drug substance impurities (Q3A), biologics, and extraneous contaminants. By analyzing the inverse relationship between qualification thresholds and maximum daily dose, professionals will gain a deeper understanding of the regulatory logic that dictates reporting, identification, and qualification requirements, as well as the nuanced application of the "whichever is lower" threshold criteria.</p>

<p>Beyond theoretical frameworks, the curriculum delves into advanced application and risk assessment methodologies essential for navigating complex stability scenarios and formulation development interdependencies. Participants will critically analyze the Q3B(R2) Attachment 3 decision tree to map compliant regulatory workflows, addressing real-world challenges such as unidentified peaks, poor mass balance, and the critical interface with ICH M7 regarding potentially mutagenic degradation products. Through detailed case studies and scenario-based assessments, the course equips quality, regulatory, and analytical professionals with the strategic expertise required to formulate robust qualification strategies utilizing metabolite data, literature safety data, and dedicated toxicity studies. Ultimately, this comprehensive training fosters the design of pre-emptive control measures and data-driven justifications, ensuring stringent audit and inspection readiness while safeguarding patient safety across the product's intended shelf life.</p>
        </div>
    </div>
</div>
